- BMRN -0.50%
Search results
- 75.52Add to watchlist-0.38 (-0.50%)At close: Fri. May 24, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open75.77High75.96Low75.12
- Mkt Cap14.34BP/E (TTM)71.25Div & YieldN/A & N/A
- Prev. Close75.9052 Wk. Low75.0352 Wk. High99.56
What analysts are sayingTop storiesBioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?Yahoo Finance · 1 day ago- BMRN -0.50%
Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...Yahoo Finance · 3 weeks agoZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and LigandYahoo Finance · 3 weeks agoRelated stocks
BioMarin is a global biotechnology company that has developed medicines to treat conditions such as achondroplasia, severe hemophilia A, and several rare inherited and lysosomal storage diseases. Learn more.
- Careers
BioMarin Pharmaceutical does not accept unsolicited resumes...
- Investor Relations
At Biomarin Pharmaceutical Inc., we promise to treat your...
- Contact Us
BioMarin RareConnections™ Tel: +1 (866) 906-6100 Fax: +1...
- Pipeline
Our pipeline includes investigational medicines across four...
- Our Science
At BioMarin, we’re committed to delivering on the promise of...
- Our Treatments
Products and Pipeline. For more than two decades, we have...
- Our Company
BioMarin is a global biotechnology company that relentlessly...
- Diseases & Conditions
Learn more about the clinical trials BioMarin is conducting...
- Products
We provide eight important treatment options for people...
- Careers
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs).
Feb 22, 2024 · BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024. February 22, 2024. Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y ...
People also ask
What does BioMarin do?
Where is BioMarin based?
Where can I learn more about BioMarin medical?
How did BioMarin start?